A Study to Assess Neuroendocrine Tumour (NET) Patients Currently Treated by Somatuline Autogel for History of Carcinoid Syndrome Associated With Episodes of Diarrhea
SYMNET
An International, Cross Sectional, Non-interventional, Study to Assess Neuroendocrine Tumour (NET) Patients Currently Treated by Somatuline Autogel for History of Carcinoid Syndrome Associated With Episodes of Diarrhea
1 other identifier
observational
340
8 countries
57
Brief Summary
The purpose of the protocol is to to assess subject's overall satisfaction regarding control of diarrhea. The study aims to supplement results obtained through clinical trials with data obtained from a population of patients receiving treatment with Somatuline Autogel in routine practice.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Oct 2010
Typical duration for all trials
57 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
October 1, 2010
CompletedFirst Submitted
Initial submission to the registry
October 20, 2010
CompletedFirst Posted
Study publicly available on registry
November 4, 2010
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2012
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2012
CompletedNovember 5, 2020
November 1, 2020
2.2 years
October 20, 2010
November 4, 2020
Conditions
Outcome Measures
Primary Outcomes (1)
Subject's overall satisfaction regarding control of diarrhea
Use of questionnaires to assess patient satisfaction (Likert scale).
Day of survey
Secondary Outcomes (1)
Impact on daily activities of the clinical manifestations of diarrhea
Day of survey
Eligibility Criteria
Out-patients
You may qualify if:
- Out-patients 18 years of age and older, who have agreed to participate in the study
- Diagnosed with a Neuroendocrine tumour (NET) and receiving treatment with Somatuline Autogel
You may not qualify if:
- Subjects for whom there are reasons that may hinder the conduct of the study (patients who have difficulty expressing themselves or who are unable to complete the questionnaires, or with insufficient data in the their files will not be enrolled in the study).
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Ipsenlead
Study Sites (57)
Teaching Hospital Brno Bohunice
Brno, Czechia
University Hospital Hradec Kralove
Hradec Králové, Czechia
Hospital Pardubice
Pardubice, Czechia
Teaching Hospital
Pilsen, Czechia
Charles University
Prague, Czechia
Teaching Hospital Na Bulovce
Prague, Czechia
CHU Angers
Angers, 49933, France
Hôpital Avicenne
Bobigny, 93009, France
Hôpital Saint André
Bordeaux, 33075, France
CHU Trousseau
Chambray-lès-Tours, 37171, France
Hôpital Beaujon
Clichy, 92118, France
CHU Michallon
Grenoble, 38043, France
Hôpital Edouard Herriot
Lyon, 69437, France
CHU Timone
Marseille, 13385, France
Hôpital Archet 2
Nice, 06202, France
Hôpital du Haut Leveque
Pessac, 33604, France
Hôpital Robert Debré
Reims, 51092, France
CHU St Etienne
Saint-Priest, 42270, France
Hôpital Rangueil
Toulouse, 31059, France
Institut Gustave-Roussy
Villejuif, 94805, France
Semmelweis University
Budapest, 1088, Hungary
Karádi-Nagy Bt.
Pécs, 7624, Hungary
Hadasit Medical Research
Jerusalem, Israel
Ospedale Regina Apostolorum
Albano Laziale, Italy
Ospedale Pesenti Fenaroli
Alzano Lombardo, Italy
Ospedale Civile
Castelfranco Veneto, Italy
Università degli Studi di Chieti
Chieti, Italy
Istituti Ospedalieri di Cremona
Cremona, Italy
Azienda Ospedaliera-Universitaria Policlinico
Modena, Italy
U.O.C. Malattie dell'Apparato Digerente e del Fegato
Roma, Italy
Unità di Endocrinologia Istituti Fisioterapici Ospitalieri
Roma, Italy
Casa Sollievo della Sofferenza
San Giovanni Rotondo, Italy
Istituto Oncologico del Mediterraneo
Viagrande, Italy
Szpital Uniwersytecki im. A. Jurasza
Bydgoszcz, Poland
Slaskiego Uniwersytetu Medycznego
Katowice, Poland
Szpital Uniwersytecki w Krakowie
Krakow, Poland
Szpital Uniwersytecki w Lodzi
Lodz, Poland
Prywatna Praktyka Lekarska
Olsztyn, Poland
Specjalistyczny Gabinet Lekarski
Poznan, Poland
Samodzielny Publiczny Szpital Kliniczny Nr 1
Szczecin, Poland
Niepubliczny Zaklad Opieki Zdrowotnej
Warsaw, Poland
Samodzielny Publiczny Centralny Szpital Kliniczny w Warszawie
Warsaw, Poland
Wojskowy Instytut Medyczny
Warsaw, Poland
Hospital Clinico Universitario de Santiago
A Coruña, Spain
Hospital De Cruces
Barakaldo, Spain
Hospital Universitari de Bellvitge
Barcelona, Spain
Hospital General Reina Sofia
Córdoba, Spain
Hospital Clinico San Carlos
Madrid, Spain
Hospital Xeral Cies de Vigo
Pontevedra, Spain
Hospital Virgen Macarena
Seville, Spain
Hospital Universitario Miguel Servet
Zaragoza, Spain
University Hospital of Wales
Cardiff, CF14 4XN, United Kingdom
University Hospital
Coventry, CV2 2DX, United Kingdom
University Hospital Aintree
Liverpool, L9 7AL, United Kingdom
Royal Free Hospital
London, United Kingdom
Chrisite Hospital Institute
Manchester, M204BX, United Kingdom
Freeman Hospital
Newcastle upon Tyne, NE7 7DN, United Kingdom
Related Publications (1)
Ruszniewski P, Valle JW, Lombard-Bohas C, Cuthbertson DJ, Perros P, Holubec L, Delle Fave G, Smith D, Niccoli P, Maisonobe P, Atlan P, Caplin ME; SYMNET study group. Patient-reported outcomes with lanreotide Autogel/Depot for carcinoid syndrome: An international observational study. Dig Liver Dis. 2016 May;48(5):552-558. doi: 10.1016/j.dld.2015.12.013. Epub 2016 Jan 15.
PMID: 26917486DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Ipsen Study Director
Ipsen
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
October 20, 2010
First Posted
November 4, 2010
Study Start
October 1, 2010
Primary Completion
December 1, 2012
Study Completion
December 1, 2012
Last Updated
November 5, 2020
Record last verified: 2020-11